title: Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma.
abstract: OBJECTIVE
  The aim of this study was to determine the safety and the efficacy of a gemcitabine/oxaliplatin combination (GEMOX) as first line therapy in patients with metastatic or unresectable locally-advanced pancreatic cancer.
  
  
  METHODS
  Patients received gemcitabine 1000 mg/m2 as a 10-mg/m2/min infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 as a 2-hour infusion, each cycle being given every 2 weeks. All patients had measurable disease and histological diagnosis before inclusion. Patients were treated until progression or for 12 cycles in the absence of progression. Tumor lesions were assessed by computed tomography scan every 4 cycles.
  
  
  RESULTS
  Between January 2001 and January 2003, 32 patients were eligible for the study. The objective response rate (OR) was 28.1% with a 12.5% complete response rate (CR). Median progression-free survival and median overall survival were 7 and 9 months, respectively. Median overall survival for patients with metastatic disease and locally-advanced disease were 7 and 25 months, respectively (P < 0.0007). Eleven patients were alive at 1 year (34.4%), six at 2 years (18.8%) and two at 3 years (6%). Fourteen (43.8%) of 32 patients experienced a clinical benefit response.
  
  
  CONCLUSIONS
  These results support the safety, the antitumor activity and the possibility of durable responses of the GEMOX regimen in patients with locally-advanced disease.
authors.affiliation: Service d'Hepato-Gastroentérologie et d'Oncologie Digestive, Hôpital L'Archet II, Nice.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Baize
authors.forename: Afaf
authors.initials: A
authors.lastname: Abu Shalaa
authors.forename: Fréderic
authors.initials: F
authors.lastname: Berthier
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Demarquay
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Bernard
authors.forename: Amine
authors.initials: A
authors.lastname: Rahili
authors.forename: Thierry
authors.initials: T
authors.lastname: Piche
authors.forename: Pierre-Michel
authors.initials: PM
authors.lastname: Huet
authors.forename: Albert
authors.initials: A
authors.lastname: Tran
authors.forename: François-Xavier
authors.initials: FX
authors.lastname: Caroli-Bosc
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D009944:Organoplatinum Compounds; D003841:Deoxycytidine